COVID-19 Therapeutics: Modality, Efficacy and Implications for Access

12:00 PM - 12:45 PM (EDT), Monday, June 14, 2021
Search General Info
Search Education
Search Partnering Companies
As COVID-19 infections spread around the world, companies moved swiftly to test many of the products in their pipelines. This has led to a broad array of novel approaches to treating patients infected with the virus—from antibodies that could be given as prevention, to treatments that help reduce the impact of the “cytokine storm,” or Acute Respiratory Distress Syndrome (ARDS). Hear from top scientists and industry leaders about the development of these non-vaccine treatment options and the challenges in achieving global access to them.
Sponsored By
Moderator
photo
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
Speakers
photo
Vice President, Infectious Diseases and Diagnostics Policy
Biotechnology Innovation Organization
photo
President, Global Pharmaceuticals, Commercial Analytics & Digital Marketing
Merck & Co., Inc.
photo
Chief Medical Officer
HHS Office of the Assistant Secretary for Preparedness and Response
photo
President, Chief Executive Officer & Director
Vir Biotechnology, Inc.
photo
Deputy Director Product Development Operations
Bill & Melinda Gates Foundation